Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

This article reviews current guidelines for managing androgenetic alopecia and highlights the need for guidelines tailored to Japan; it reports no new clinical results.

This study concluded that five-alpha-reductase inhibitors may reduce prostate cancer risk but could increase the risk of high-grade prostate cancer in men regularly screened for the disease.

This study found that finasteride (1 mg) significantly increased hair growth in all scalp regions affected by male pattern hair loss over 24 months in men aged 18 to 60, with more pronounced effects in younger men.

This review examines medical literature on postfinasteride syndrome and reports no new results; the authors call for more controlled studies on permanent sexual dysfunction and mood changes linked to 5-alpha-reductase inhibitors.

This article states that hormone therapy with estrogens and antiandrogens for transgender females is within an obstetrician-gynecologist's practice scope and involves careful dosing and monitoring to manage short-term thrombotic risks.

In this study, finasteride was found to be more effective than 5% minoxidil for treating male androgenetic alopecia in Chinese patients, with combination therapy showing the greatest improvement.

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.

This study reviewed Woodhouse-Sakati syndrome and found it consistently associated with hypogonadism, decreased IGF1, and frontotemporal alopecia, with additional symptoms like intellectual disabilities and diabetes in some patients.

This review discusses the efficacy and safety of 5-alpha reductase inhibitors for treating androgenetic alopecia, noting concerns about sexual side effects, which are typically uncommon and often resolve over time.

This review examines recent approvals and emerging treatments for androgenetic alopecia, discussing newly approved drugs like Propecia and Rogaine Extra Strength 5%, but without presenting new clinical results.

This review discusses the hormonal influences on prostate carcinogenesis and notes ongoing trials investigating whether finasteride could reduce prostate cancer incidence by inhibiting dihydrotestosterone synthesis, but it reports no new results.

This study found that reproductive gynecologists are the primary source of referrals for male infertility evaluations, with many men referred before completing a male factor investigation even when using assisted reproductive technologies or lifestyle factors like testosterone replacement.

This review discusses the risk factors and implications of sperm aneuploidy in males, and it reports no new clinical results; the authors highlight the importance of personalized assessment in assisted reproduction.

In this randomized clinical trial, the authors reported that adipose-derived stem cell constituent extract topical solution increased hair density and thickness in patients with androgenetic alopecia over 16 weeks compared to placebo.

Testosterone therapy aims to treat hormone deficiencies and various conditions safely and effectively, but requires careful patient monitoring due to potential side effects.

In this study, androgen receptors were found only in the mane follicles of red deer stags during the breeding season, suggesting their expression is induced by seasonal hormone changes.

This review discusses the impact of COVID-19 on the endocrine system and reports no clinical results; the authors emphasize the need to investigate endocrine damage during and after COVID-19 infection.

This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.

This review discusses the physiological basis, history, and current development of male hormonal contraception, highlighting its potential risks and benefits, but reports no new research findings.

This article discusses androgenetic alopecia and reports no new clinical results.

This review examines the diverse roles of SRD5α enzymes across species, focusing on their involvement in steroid synthesis, sexual development, and various physiological processes, but reports no new clinical results.

This review discusses cross-sex hormone therapy for managing gender dysphoria in transsexual individuals and reports no new clinical results; it highlights the need for education and culturally sensitive training for healthcare professionals.

In this laboratory study with rats, treatment with finasteride reduced dihydrotestosterone levels and fertility parameters, with a 30-day recovery period proving insufficient to fully restore sperm function and fertility.

This review discusses the role of androgen hormones in skin and hair conditions and highlights the potential of antiandrogen therapies in dermatology, reporting no new results.

Hormones and genetics play key roles in male and female baldness, which can affect mental health and may be linked to other health issues.

This article discusses concerns and recommendations from a French-speaking andrology society regarding COVID-19's potential impact on men's reproductive health and calls for further research in this area.

This review indicates that many former FDA category D and X systemic dermatologic medications may negatively impact male fertility, with further research needed to assess potential teratogenic effects.

This study found that chronic exposure to finasteride did not significantly impact spermatogenesis in rats.

This chapter reviews selective androgen receptor modulators, discussing their therapeutic potential beyond current androgen applications, and reports no new clinical findings.